Clinical Research Details Clinical Research A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis. (20222253) Study Description A study to test whether different doses of BI 1291583 help people with bronchiectasis. This study is being done to test the study drug, BI 1291583, for safety, effectiveness, and side effects, when compared to taking a placebo, in subjects with bronchiectasis and find the recommended dose of the study drug, BI 1291583 that can be used in future clinical research studies. Different doses of the study drug will be tested to see which dose has less unacceptable side effects and is more effective in subjects with bronchiectasis. Inclusion/Exclusion Criteria Main inclusion criteria: ? ≥18 and ≤85 years ? Clinical history consistent with bronchiectasis and investigator confirmed diagnosis by computed tomography (CT) scan ? History of 2 pulmonary exacerbations requiring antibiotic treatment in the last 12 months, or 1 exacerbation if SGRQ Symptoms score is >40 ? Current sputum producers with a history of chronic expectoration, able to provide spontaneous sputum at Screening Main exclusion criteria: ? Cystic fibrosis, hypogammaglobulinemia, common variable immunodeficiency, α1-antitrypsin deficiency treated with augmentation therapy, current allergic bronchopulmonary aspergillosis ? Acute infections ? Unstable dose regimen of maintenance bronchiectasis treatment Investigators Mehdi S. Mirsaeidi, M.D., M.P.H. Medicine